Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells. Immunization with recombinant YFV17D vector prime followed by HIV-1 CH505 TF gp120 protein boosts were able to induce neutralizing antibodies for a HIV-1 tier 1 isolate in mice. This modified YFV vector may be a starting point for constructing HIV-1 vaccine candidate priming vectors.
Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120
Yu, J-S., Liao, H-X., Pritchett, J., Bowman, C., Vivian, C., Parks, R., Xia, S-M., Cooper, M., Williams, W. B., Bonsignori, M., Reed, S. G., Chen, M., Vandergrift, N., Rice, C. M., & Haynes, B. F. (2017). Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Journal of Virological Methods, 249, 85-93. https://doi.org/10.1016/j.jviromet.2017.08.012
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Treatment preferences among patients with mild-to-moderate atopic dermatitis
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Spatiotemporal analysis exploring the effect of law enforcement drug market disruptions on overdose, Indianapolis, Indiana, 2020-2021